Read by QxMD icon Read

Journal of Child and Adolescent Psychopharmacology

Kathryn R Cullen, Palistha Amatya, Mark G Roback, Christina Sophia Albott, Melinda Westlund Schreiner, Yanan Ren, Lynn E Eberly, Patricia Carstedt, Ali Samikoglu, Meredith Gunlicks-Stoessel, Kristina Reigstad, Nathan Horek, Susannah Tye, Kelvin O Lim, Bonnie Klimes-Dougan
BACKGROUND: Novel interventions for treatment-resistant depression (TRD) in adolescents are urgently needed. Ketamine has been studied in adults with TRD, but little information is available for adolescents. This study investigated efficacy and tolerability of intravenous ketamine in adolescents with TRD, and explored clinical response predictors. METHODS: Adolescents, 12-18 years of age, with TRD (failure to respond to two previous antidepressant trials) were administered six ketamine (0...
July 13, 2018: Journal of Child and Adolescent Psychopharmacology
Jonathan Channing, Mary Mitchell, Samuele Cortese
OBJECTIVE: To perform a systematic review of studies of lurasidone in children and/or adolescents and to present a case report aimed to add further insights into its use in clinical practice with youth. METHODS: We searched the following databases for empirical studies, of any design, focusing on the pharmacokinetics, efficacy, or safety of lurasidone in children and/or adolescents: Pubmed (Medline), OVID (PsycInfo, EMBASE+EMBASE classic, OVID Medline), Web of Knowledge, and ClinicalTrials...
July 13, 2018: Journal of Child and Adolescent Psychopharmacology
Inmaculada Baeza, Elena de la Serna, Rosa Calvo-Escalona, Jessica Merchán-Naranjo, Pamela Rodríguez-Latorre, M Carmen Martínez-Cantarero, Patricia Andrés, José Angel Alda, Daniel Muñoz-Samons, Daniel Ilzarbe, Celso Arango, Josefina Castro-Fornieles
OBJECTIVE: To analyze liver function tests (LFT), weight, metabolic syndrome (MetS) and at risk of meeting MetS criteria (AR-MetS) in children and adolescents on antipsychotics (AP) during a year-long follow-up. METHODS: Two hundred sixteen patients, AP naïve or quasi-naïve (<30 days on AP), were included. Total bilirubin, the enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), weight and other parameters of MetS were measured at baseline, and at 3, 6 and 12 months, while patients remained on the same AP...
July 5, 2018: Journal of Child and Adolescent Psychopharmacology
Patricia Gassó, Ana Blázquez, Natalia Rodríguez, Daniel Boloc, Teresa Torres, Sergi Mas, Amalia Lafuente, Luisa Lázaro
OBJECTIVE: Fluoxetine is an effective and well-tolerated pharmacological treatment for children and adolescents with major depressive disorder (MDD). However, a high percentage of patients do not respond. There is a substantial genetic contribution to this variable clinical outcome. Based on previous genetic results of our group and given the lack of pharmacogenetics studies of antidepressant response with a long follow-up period, we evaluated the influence of single nucleotide polymorphisms (SNPs) in genes related to the serotonergic pathway on remission and recovery in children and adolescents diagnosed with MDD after 12 months of initiating fluoxetine treatment...
July 5, 2018: Journal of Child and Adolescent Psychopharmacology
Mehmet Burcu, Julie M Zito, Daniel J Safer, Laurence S Magder, Susan dosReis, Fadia T Shaya, Geoffrey L Rosenthal
OBJECTIVE: To assess the risk of incident cardiovascular events that led to hospitalizations or emergency department visits following atypical antipsychotic (AAP) treatment initiation in youth according to dose, duration of use, and concomitant use of leading psychotropic medication classes. METHODS: We used computerized Medicaid claims to conduct a retrospective cohort study of youth (5-20 years) who initiated AAP treatment. AAP use was operationalized in a time-dependent manner according to current vs...
July 5, 2018: Journal of Child and Adolescent Psychopharmacology
Giovanni A Salum, Circe S Petersen, Rafaela B Jarros, Rudineia Toazza, Diogo DeSousa, Lidiane Nunes Borba, Stela Castro, Julia Gallegos, Paula Barrett, Rany Abend, Yair Bar-Haim, Daniel S Pine, Silvia H Koller, Gisele G Manfro
BACKGROUND: The objective of this study is to assess group differences in symptom reduction between individuals receiving group cognitive behavioral therapy (G-CBT) and attention bias modification (ABM) compared to their respective control interventions, control therapy (CT), and attention control training (ACT), in a 2 × 2 factorial design. METHODS: A total of 310 treatment-naive children (7-11 years of age) were assessed for eligibility and 79 children with generalized, separation or social anxiety disorder were randomized and received G-CBT (n = 42) or CT (n = 37)...
July 3, 2018: Journal of Child and Adolescent Psychopharmacology
Muhammad A Parvaz, Kristen Kim, Sean Froudist-Walsh, Jeffrey H Newcorn, Iliyan Ivanov
OBJECTIVE: Attention-deficit/hyperactivity disorder (ADHD) is associated with elevated risk for later development of substance use disorders (SUD), specifically because youth with ADHD, similar to individuals with SUD, exhibit deficits in learning abilities and reward processing. Another known risk factor for SUD is familial history of substance dependence. Youth with familial SUD history show reward processing deficits, higher prevalence of externalizing disorders, and higher impulsivity scores...
June 20, 2018: Journal of Child and Adolescent Psychopharmacology
Jerome H Taylor, Ewgeni Jakubovski, Daniel Gabriel, Michael H Bloch
BACKGROUND: Antipsychotic-related weight gain is a common clinically relevant side effect when treating psychotic disorders in pediatric populations, yet few predictors and no moderators of antipsychotic-related weight gain are known. METHODS: The Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study randomized 119 youths (age 8-19 years) with schizophrenia or schizoaffective disorder to 8 weeks of antipsychotic treatment with molindone, risperidone, or olanzapine and assessed treatment response and side effects...
June 19, 2018: Journal of Child and Adolescent Psychopharmacology
Johanna Inhyang Kim, Jae-Won Kim, Inkyung Shin, Bung-Nyun Kim
OBJECTIVES: Environmental factors may interact with genetic factors via the epigenetic process, and this interaction can contribute to inter-individual variability in the treatment response. The purpose of this study was to investigate the interaction effects between dopamine receptor D4 (DRD4) methylation and prenatal maternal stress on the methylphenidate (MPH) response of youth with attention-deficit/hyperactivity disorder (ADHD). METHODS: This study was an 8-week open-label trial of MPH that included 74 ADHD youth...
June 15, 2018: Journal of Child and Adolescent Psychopharmacology
Alberto José Cerrillo-Urbina, Antonio García-Hermoso, María Jesús Pardo-Guijarro, Mairena Sánchez-López, José Luis Santos-Gómez, Vicente Martínez-Vizcaíno
OBJECTIVE: The aim of this study was to assess the efficacy and safety of stimulant and nonstimulant medications in children and adolescents using as an outcome measure the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV), and to examine the effect of medications in different ADHD subtypes (i.e., inattention and hyperactivity/impulsivity). METHODS: MEDLINE, Scopus, EMBASE, EBSCO (E-journal, CINAHL and SportDiscus), PUBMED, and The Cochrane Central Register of Controlled Trials databases were searched...
June 13, 2018: Journal of Child and Adolescent Psychopharmacology
Yasuyuki Okumura, Masahide Usami, Takashi Okada, Takuya Saito, Hideki Negoro, Noa Tsujii, Junichi Fujita, Junzo Iida
OBJECTIVE: We aimed to evaluate glucose and prolactin monitoring in children and adolescents initiating antipsychotic therapy using a nationwide claims database. METHODS: A retrospective 15-month cohort study was conducted using the National Database of Health Insurance Claim Information and Specified Medical Checkups in Japan. Patients aged ≤18 years, who were newly prescribed antipsychotics between April 2014 and March 2015, were followed up for 450 days. Outcomes were the use of glucose and prolactin testing through 15 months after drug initiation (index date) with consideration of persistence with antipsychotic therapy...
June 11, 2018: Journal of Child and Adolescent Psychopharmacology
Lior Schapir, Abraham Weizman, Pavel Golubchik
OBJECTIVES: Treatment with selective serotonin reuptake inhibitors (SSRIs) is common and is considered safe and effective in the treatment of anxiety and depressive disorders in pediatric populations. SSRI administration, however, is associated with adverse metabolic effects. The aim of this preliminary study was to evaluate the possible influence of a 6-month SSRI treatment on metabolic parameters in children and adolescents with depressive and/or anxiety disorders. METHODS: Metabolic parameters (glucose, cholesterol, triglycerides, low-density lipoprotein [LDL], and high-density lipoprotein [HDL]) were monitored in 22 children and adolescents (16 boys and 6 girls, aged 8-18 years) at baseline and after 6 months of SSRI treatment for depression and/or anxiety...
June 6, 2018: Journal of Child and Adolescent Psychopharmacology
Marta Carulla-Roig, Kayoko Isomura, Ana Pérez-Vigil, Henrik Larsson, Clara Hellner, David Mataix-Cols, Lorena Fernández de la Cruz
BACKGROUND: Monitoring "real world" dispensation patterns over time is important to build the evidence base for safe and efficient use of psychotropic drugs. In this study, we aimed to comprehensively examine the patterns of psychotropic drug dispensations in patients with Tourette and chronic tic disorders (TD/CTD) in Sweden between 2005 and 2013. METHODS: A cohort of 6979 TD/CTD patients was identified through the Swedish National Patient Register. Their drug dispensation patterns, collected in the Swedish Prescribed Drug Register, were examined between July 1, 2005 and December 31, 2013...
June 5, 2018: Journal of Child and Adolescent Psychopharmacology
Kiki Chang, Melissa DelBello, Amy Garrett, Ryan Kelley, Meghan Howe, Cal Adler, Jeffrey Welge, Stephen M Strakowski, Manpreet Singh
OBJECTIVES: Prior studies have shown that youth with bipolar disorder demonstrate neurofunctional changes in key prefrontal and subcortical brain regions implicated in emotional regulation following treatment with pharmacological agents. We recently reported a large response rate (>60%) to quetiapine (QUET) for treating depressive symptoms in adolescents with bipolar depression. This study investigates the neurofunctional effects of QUET using functional magnetic resonance imaging (fMRI)...
May 30, 2018: Journal of Child and Adolescent Psychopharmacology
Nnenna Kalaya Okereke
No abstract text is available yet for this article.
May 29, 2018: Journal of Child and Adolescent Psychopharmacology
Ashley R Smith, Eric E Nelson, Brent I Rappaport, Daniel S Pine, Ellen Leibenluft, Johanna M Jarcho
OBJECTIVE: Socially anxious adolescents report distress during social decision-making, wherein their favorable view of peers directly conflicts with their expectation to be viewed negatively by peers; a phenomenon we refer to as "mismatch bias." The present study utilizes a novel paradigm with dynamic social stimuli to explore the correlates of mismatch biases in anxious and healthy youth. METHOD: The behavioral and neural correlates of mismatch biases were assessed in healthy (N = 17) and anxious (N = 14) youth during functional MRI...
May 24, 2018: Journal of Child and Adolescent Psychopharmacology
Raman Baweja, Sara Mills, James Waxmonsky
No abstract text is available yet for this article.
May 21, 2018: Journal of Child and Adolescent Psychopharmacology
Oliver Scholle, Tobias Banaschewski, Dirk Enders, Edeltraut Garbe, Oliver Riedel
OBJECTIVE: Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) frequently have comorbidities that are potential indications for antipsychotics (APs). Some studies have suggested that the combined use of methylphenidate (MPH) and APs is increasing in this population group. Longitudinal analyses and in-depth investigations on the substance level are lacking. This study aimed to estimate the cumulative proportion of concomitant AP/MPH use in children and adolescents with ADHD over a follow-up of up to 9 years and to describe patient characteristics stratified by specific AP drug...
May 16, 2018: Journal of Child and Adolescent Psychopharmacology
Yvette E Lentferink, Ewoudt M W van de Garde, Catherijne A J Knibbe, Marja M J van der Vorst
OBJECTIVES: Attention-deficit/hyperactivity disorder (ADHD) is often treated with psychostimulants. Psychostimulants' adverse effects on body mass index standard deviation score (BMI-sds) and height in children/adolescents with ADHD have been reported. However, literature is inconsistent, and it is unclear whether the observed effects are dosage- and/or BMI-dependent. Therefore, the aim of this retrospective observational study is to evaluate the influence of psychostimulants on BMI-sds and height-sds in a pediatric cohort with ADHD from an outpatient clinic, and to study the correlation between psychostimulant dosage and BMI-sds and height-sds change...
May 16, 2018: Journal of Child and Adolescent Psychopharmacology
Louis T van Zyl, Sharon A Chung, Azmeh Shahid, Colin M Shapiro
OBJECTIVE: Parasomnias are common in childhood but there is no established treatment for parasomnias. The aim of this study was to (1) report on the outcome of using L-tryptophan to manage parasomnias in children and (2) examine sleep architecture and subjective psychological/sleep symptoms in children with parasomnia. METHOD: A retrospective analysis was conducted of charts of children (3-18 years old) who underwent polysomnographic testing and were diagnosed with primary parasomnia...
May 9, 2018: Journal of Child and Adolescent Psychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"